• Suzuki has just introduced the Moorai, a $3,000 robotic transport dog designed to redefine personal mobility. This futuristic machine is part of Suzuki’s push toward intelligent robotic platforms and was showcased at the Japan Mobility Show as a bold statement of innovation. With a form inspired by canine agility and robotic strength, the Moorai allows users to sit atop and be transported autonomously across varied terrain—blending entertainment, convenience, and high-tech design in one compact, functional ride.

    Built on technology derived from Suzuki’s more advanced MOQBA platform, the Moorai is ideal for both everyday fun and practical short-range mobility. Its quadrupedal design allows it to navigate uneven paths, indoor environments, or even emergency zones, offering hands-free transit at speeds up to 20 mph. At just $3,000, it's one of the most accessible robotic mobility systems available—and marks the dawn of robotic pets you can actually ride.

    #SuzukiInnovation #RoboticMobility #TechFuture #AITransportation
    #NextGenRobots
    Suzuki has just introduced the Moorai, a $3,000 robotic transport dog designed to redefine personal mobility. This futuristic machine is part of Suzuki’s push toward intelligent robotic platforms and was showcased at the Japan Mobility Show as a bold statement of innovation. With a form inspired by canine agility and robotic strength, the Moorai allows users to sit atop and be transported autonomously across varied terrain—blending entertainment, convenience, and high-tech design in one compact, functional ride. Built on technology derived from Suzuki’s more advanced MOQBA platform, the Moorai is ideal for both everyday fun and practical short-range mobility. Its quadrupedal design allows it to navigate uneven paths, indoor environments, or even emergency zones, offering hands-free transit at speeds up to 20 mph. At just $3,000, it's one of the most accessible robotic mobility systems available—and marks the dawn of robotic pets you can actually ride. #SuzukiInnovation #RoboticMobility #TechFuture #AITransportation #NextGenRobots
    0 Комментарии 0 Поделились 23Кб Просмотры
  • China has reportedly made a significant breakthrough in directed-energy weaponry by developing a high-power microwave (HPM) gun capable of firing over 10,000 rounds without malfunction.

    This development comes from the Northwest Institute of Nuclear Technology (NINT), a research arm of China’s military sector.

    The microwave weapon is designed to disable or destroy electronic components in drones, missiles, and potentially satellites, using bursts of focused electromagnetic energy.

    The team’s research was recently published in the peer-reviewed journal High Power Laser and Particle Beams, lending credibility to the technical claims.

    What sets this system apart is its durability and compactness.

    Traditional HPM weapons often face challenges maintaining vacuum integrity in their tubes after prolonged use, but this new design incorporates advanced ceramic-metal welding and a self-regenerating vacuum mechanism.

    These innovations have enabled it to deliver thousands of shots at power levels in the hundreds of megawatts, while operating with a pulsed current reaching 3 gigawatts.

    According to the study, the weapon can emit 10 to 30 powerful pulses per second, with electric field strengths comparable to those caused by nuclear electromagnetic pulses (EMPs).

    This technology is especially significant for modern warfare, where drones and electronics-driven systems dominate battlefields.

    Microwave weapons like this one could be deployed on vehicles to create electronic dead zones, disabling enemy assets without physical destruction.

    It also signals that China is attempting to leap ahead in the arms race for non-kinetic weapons, competing with the U.S., Russia, and the EU, all of which are also developing similar systems.

    While China has already demonstrated both solid-state (GaN-based) and vacuum tube-based designs, this latest innovation may offer enhanced battlefield longevity and performance.
    China has reportedly made a significant breakthrough in directed-energy weaponry by developing a high-power microwave (HPM) gun capable of firing over 10,000 rounds without malfunction. This development comes from the Northwest Institute of Nuclear Technology (NINT), a research arm of China’s military sector. The microwave weapon is designed to disable or destroy electronic components in drones, missiles, and potentially satellites, using bursts of focused electromagnetic energy. The team’s research was recently published in the peer-reviewed journal High Power Laser and Particle Beams, lending credibility to the technical claims. What sets this system apart is its durability and compactness. Traditional HPM weapons often face challenges maintaining vacuum integrity in their tubes after prolonged use, but this new design incorporates advanced ceramic-metal welding and a self-regenerating vacuum mechanism. These innovations have enabled it to deliver thousands of shots at power levels in the hundreds of megawatts, while operating with a pulsed current reaching 3 gigawatts. According to the study, the weapon can emit 10 to 30 powerful pulses per second, with electric field strengths comparable to those caused by nuclear electromagnetic pulses (EMPs). This technology is especially significant for modern warfare, where drones and electronics-driven systems dominate battlefields. Microwave weapons like this one could be deployed on vehicles to create electronic dead zones, disabling enemy assets without physical destruction. It also signals that China is attempting to leap ahead in the arms race for non-kinetic weapons, competing with the U.S., Russia, and the EU, all of which are also developing similar systems. While China has already demonstrated both solid-state (GaN-based) and vacuum tube-based designs, this latest innovation may offer enhanced battlefield longevity and performance.
    0 Комментарии 0 Поделились 22Кб Просмотры
  • In a landmark medical advancement, researchers at Newcastle University have successfully created a 3D-printed human cornea using stem cells, collagen, and alginate to form a bio-ink. This innovation offers renewed hope to more than 10 million people globally who suffer from corneal blindness due to disease, trauma, or infection. The 3D printing process can produce custom-shaped corneas in under 10 minutes, tailored precisely to each patient using a simple eye scan.

    What makes this technology even more promising is its potential to ease the global shortage of donor corneas. Since bio-printed corneas are derived from a patient’s own stem cells, the risk of rejection could be significantly reduced. While clinical trials and regulatory hurdles remain before these corneas can be widely used in patients, this achievement marks a massive step toward revolutionizing eye care and restoring sight for millions.

    #3DPrinting #StemCellTherapy #VisionRestoration #MedicalInnovation
    #Bioengineering
    In a landmark medical advancement, researchers at Newcastle University have successfully created a 3D-printed human cornea using stem cells, collagen, and alginate to form a bio-ink. This innovation offers renewed hope to more than 10 million people globally who suffer from corneal blindness due to disease, trauma, or infection. The 3D printing process can produce custom-shaped corneas in under 10 minutes, tailored precisely to each patient using a simple eye scan. What makes this technology even more promising is its potential to ease the global shortage of donor corneas. Since bio-printed corneas are derived from a patient’s own stem cells, the risk of rejection could be significantly reduced. While clinical trials and regulatory hurdles remain before these corneas can be widely used in patients, this achievement marks a massive step toward revolutionizing eye care and restoring sight for millions. #3DPrinting #StemCellTherapy #VisionRestoration #MedicalInnovation #Bioengineering
    0 Комментарии 0 Поделились 22Кб Просмотры
  • winton , overwatch :3

    #dva #dvacosplay #cosplay #overwatch #cosplaygirl #gamer #gamergirl #fyp
    winton , overwatch :3 #dva #dvacosplay #cosplay #overwatch #cosplaygirl #gamer #gamergirl #fyp
    0 Комментарии 0 Поделились 22Кб Просмотры
  • Scientists at the University of Sunderland, led by Dr. Maria Teresa Borrello, have developed two experimental drugs—DR-3 and FDR2—that target the enzyme HDAC6.

    These drugs have shown promise in halting or reversing liver fibrosis, a condition characterized by the accumulation of scar tissue in the liver.

    Research Overview

    The research, published in The FEBS Journal, focuses on the role of HDAC6 in liver fibrosis.

    HDAC6 is involved in regulating inflammation and the activation of hepatic stellate cells, which are responsible for producing collagen and contributing to scar tissue formation.

    By inhibiting HDAC6, the experimental drugs aim to reduce inflammation and prevent the activation of these stellate cells, thereby mitigating fibrosis progression.

    Laboratory Findings

    In laboratory settings, the HDAC6 inhibitors DR-3 and FDR2 demonstrated high selectivity for HDAC6 over other histone deacetylases.

    They effectively reduced markers of hepatic stellate cell activation and fibrogenic gene expression.

    Additionally, these compounds increased acetylation of α-tubulin and suppressed TGF-β1-induced SMAD signaling, which are key pathways in fibrosis development.

    Ex Vivo Human Liver Models

    The efficacy of DR-3 and FDR2 was further validated using human precision-cut liver slices (hPCLS), an ex vivo model that closely mimics human liver tissue.

    Treatment with these inhibitors resulted in reduced fibrogenic protein levels and collagen deposition, indicating their potential to reverse existing fibrosis.

    Importantly, these effects were achieved without significant toxicity to the liver tissue.

    Clinical Implications

    The British Liver Trust has welcomed these findings, highlighting their potential to transform care for the UK's estimated two million liver fibrosis patients, many of whom are diagnosed at advanced stages of the disease.

    While these results are promising, the drugs are still in the experimental phase and have not yet undergone human clinical trials. Nevertheless, they offer a targeted therapeutic approach that could eventually become a lifesaving treatment worldwide.
    Scientists at the University of Sunderland, led by Dr. Maria Teresa Borrello, have developed two experimental drugs—DR-3 and FDR2—that target the enzyme HDAC6. These drugs have shown promise in halting or reversing liver fibrosis, a condition characterized by the accumulation of scar tissue in the liver. Research Overview The research, published in The FEBS Journal, focuses on the role of HDAC6 in liver fibrosis. HDAC6 is involved in regulating inflammation and the activation of hepatic stellate cells, which are responsible for producing collagen and contributing to scar tissue formation. By inhibiting HDAC6, the experimental drugs aim to reduce inflammation and prevent the activation of these stellate cells, thereby mitigating fibrosis progression. Laboratory Findings In laboratory settings, the HDAC6 inhibitors DR-3 and FDR2 demonstrated high selectivity for HDAC6 over other histone deacetylases. They effectively reduced markers of hepatic stellate cell activation and fibrogenic gene expression. Additionally, these compounds increased acetylation of α-tubulin and suppressed TGF-β1-induced SMAD signaling, which are key pathways in fibrosis development. Ex Vivo Human Liver Models The efficacy of DR-3 and FDR2 was further validated using human precision-cut liver slices (hPCLS), an ex vivo model that closely mimics human liver tissue. Treatment with these inhibitors resulted in reduced fibrogenic protein levels and collagen deposition, indicating their potential to reverse existing fibrosis. Importantly, these effects were achieved without significant toxicity to the liver tissue. Clinical Implications The British Liver Trust has welcomed these findings, highlighting their potential to transform care for the UK's estimated two million liver fibrosis patients, many of whom are diagnosed at advanced stages of the disease. While these results are promising, the drugs are still in the experimental phase and have not yet undergone human clinical trials. Nevertheless, they offer a targeted therapeutic approach that could eventually become a lifesaving treatment worldwide.
    0 Комментарии 0 Поделились 22Кб Просмотры
Расширенные страницы